Faron’s Post

Excellent opening presentation at Life Science Open Space Summit in Kraków by keynote speaker Thierry Marchal highlighting the important need to accelerate drug discovery process in oncology. He emphasized the crucial role of #collaboration and #digitaltransformation with simplified tools in building a bright future of #healthcare. #LSOS24 #datamanagement

💡 Our wonderful Oncology Therapeutic Experts at ICON Biotech collaborated with Citeline and industry specialist to uncover how new wave technology-driven therapeutics are reshaping oncology development!   Have a read through the insightful discussion and feel free to reach out if you would like to connect with Andreas Dreps and Muaiad Kittaneh for a chat!   #oncologydevelopment #emergingtechnologies #clinicalresearch

The Booster Innovation Fund is thrilled to welcome ground-breaking cancer therapy company BioOra into its portfolio.   BioOra uses CAR T-cell therapy to modify a patient’s own immune cells (T-cells) to fight cancer cells.    Founded in collaboration with Malaghan Institute of Medical Research, Bio Ora is on a mission to make this treatment available and affordable in New Zealand.   The company is commercialising an automated manufacturing process that significantly reduces patient costs and improves accessibility to this transformative treatment.   We’re proud to be investing alongside lead investor BridgeWest Ventures in this exciting company!   Disclosure: Booster Investment Management Limited is the issuer of the Booster Innovation Scheme, Booster Innovation Fund (Fund). The Fund’s Product Disclosure Statements are available at www.booster.co.nz or by contacting your financial adviser. #Tech #MedicalTech #Innovation #Boosternz #BIF

💡 Our wonderful Oncology Therapeutic Experts at ICON Biotech collaborated with Citeline and industry specialist to uncover how new wave technology-driven therapeutics are reshaping oncology development! Have a read through the insightful discussion and feel free to reach out if you would like to connect with Andreas Dreps and Muaiad Kittaneh for a chat! #oncologydevelopment #emergingtechnologies #clinicalresearch

Read what the experts think about current and future innovations in oncology drug development....

💡 Our wonderful Oncology therapeutic experts at ICON Biotech collaborated with Citeline and industry specialists to explore how innovative, technology-driven therapeutics are reshaping the future of oncology development. We invite you to explore this insightful discussion and do not hesitate to reach out if you would like to connect with Andreas Dreps and Muaiad Kittaneh for a chat. #oncologydevelopment #emergingtechnologies #clinicalresearch

Iterating toward 90% clinical success rates in oncology trials. In oncology, the success rate of clinical trials is a staggering 10%. I believe computational technology holds the key to flipping that number, but it's hard to predict which approach will create the next quantum leap. To build the future faster, we are launching CAST—Critical Assessment of Techniques for Trial Outcome Prediction. CAST is a benchmarking platform designed to test, refine, and compare methods for predicting clinical efficacy. 🎯 Goal: Iterating toward 90% clinical success rates in oncology trials. 💡 Who can join? Whoever dares. 🔬 Methodology: Whatever works. Read our Manifesto 👉 https://lnkd.in/dCtsJUvU #CAST #Biotech #CancerResearch #ClinicalTrials #Innovation

In a survey of practices in The US Oncology Network, 52% said they rarely or never interact with life sciences company representatives. In the video below, Ontada Learn VP & GM Claude Bergeron shares how tools like our eLearn Now can support and complement both practices and life sciences companies by sharing relevant information when providers need it most. #LifeSciences #ProviderEducation

Sunday at ESMO! Markets sometimes seemingly fight against innovation, but innovators are persistent, tenacious, and determined. Henry Ford saw a future that didn’t exist at the time and how to redefine transportation and not just incrementally improve horse-drawn carriages. The biopharma history book is replete with examples of treatments which weren’t readily accepted nor thought plausible when the existing paradigm began to be challenged. That innovation often needs a boost and an enabling voice to attack the marketplace and status quo. At Inizio, we are a leading, scalable commercialization platform to help biopharma companies at pivotal moments from early asset development through to market. We can help you tell the story of your equivalent of disrupting the horse-drawn carriage! Come talk to us at booth 431e at the ESMO exhibit hall in Barcelona! We can invent a future that doesn’t currently exist together. #Inizio #ESMO2024 #ReimagineHealth #Oncology #Biopharma #Healthcare

🚀 Potential Advantages of Dual-Payload ADCs: Enhanced Efficacy: Target multiple cancer pathways for stronger tumor suppression. Synergistic Effects: Combined drugs can work together for greater impact. Broader Therapeutic Window: Lower doses of each drug, reducing toxicity while maintaining effectiveness. Flexibility: Address tumor heterogeneity with dual-targeted therapy. 🔧 Current Challenges of Dual-Payload ADCs: Complexity in Manufacturing: Ensuring batch consistency and stability with two distinct payloads is difficult. At T-E Meds, an affiliate of Immunwork, we have developed a proprietary platform that overcomes these manufacturing challenges and produces dual-payload ADCs with superior efficacy. Join Dr. Art Hsing-Mao Chu, CEO of T-E Meds, at the World ADC San Diego conference on Nov 4th to hear more about our breakthrough technology. 🤝 Partnering opportunities are welcome! World ADC Event Series #ADC #Biotech #CancerTherapy #WorldADC #Partnership